CTN: Northern New England Node

CTN：新英格兰北部节点

• 批准号: 7580361
• 负责人: Roger D. Weiss
• 金额: $ 94.53万
• 依托单位: MCLEAN HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-30 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7580361
• 关键词: Adherence; Adopted; Arts; Attention deficit hyperactivity disorder; Caring; Clinical; Clinical Trials Network; Communities; Dependence; Development; Drug abuse; Evidence based practice; Funding; HIV; Health Personnel; Intervention; Lead; Leadership; Life; Maintenance; Methadone; Mission; National Institute of Drug Abuse; New England; Numbers; Opioid Analgesics; Participant; Patients; Performance; Pharmaceutical Preparations; Play; Progress Reports; Randomized; Randomized Controlled Clinical Trials; Rate; Reporting; Research; Research Personnel; Role; Science; Site; Substance Use Disorder; Testing; Universities; Viral Load result; Work; addiction; base; design; expectation; improved; member; prescription document; prescription procedure; programs; response; treatment program

This is a proposal for renewal of "Clinical Trials Network (CTN): Harvard University Northern New England Node," submitted in response to RFA-DA-07-001 "Announcement of a Limited Competition of the National Drug Abuse Treatment Clinical Trials Network (U10)." The Northern New England Node (NNEN) brings together research expertise, sophisticated community treatment programs (CTPs), and a wide variety of patients being treated in diverse settings and multiple levels of care. The Node is characterized by a partnership between academic researchers and community-based treatment providers throughout 5 New England states to design and implement addiction treatment studies in community-based treatment programs. The NNEN has demonstrated outstanding progress since entering the CTN in 2002, with a combination of scientific and administrative leadership and excellent trial performance. The NNEN is the Lead Node on a multi-site study of prescription opioid analgesic dependence treatment, and has played a major scientific leadership role in the development and implementation of two CTN studies of patients with substance use disorder and attention deficit hyperactivity disorder. Administrative leadership is exemplified by participation by NNEN members on the 4 key CTN national committees; the NNEN is the only Node to be represented on all of these committees. NNEN members have also been elected to chair several national committees and work groups, demonstrating their excellent reputation among their CTN colleagues. Trial performance has been exemplary: the NNEN has participated in more trials and randomized more participants than any other Node entering in 2002; and has randomized more than twice as many participants in the 2005-2006 Node Trial Performance Report than the average for a CTN Node. Moreover, according to the most recent NIDA Trial Progress Report, the NNEN is the only Node (other than the 2 new Nodes entering the CTN in 2005) to meet or exceed expectations on every performance indicator of every trial the Node has entered. NNEN CTPs have adopted a number of new evidence-based practices, and have themselves disseminated information about these practices regionally, nationally, and internationally. This proposal highlights the accomplishments of the Northern New England Node in the funding period since September 2002. While the Node has made outstanding progress, the proposal also details a number of enhancements to strengthen the NNEN during the renewal period. During the next three years, the NNEN plans to continue to advance the mission of the CTN by implementing and testing state-of-the-art drug abuse treatment interventions, so that clinical programs will use the best treatments available and patients will receive the full benefit of the evolving science of addiction treatment.

这是续签“临床试验网络（CTN）：哈佛大学北部新的提案 英格兰节点，“针对RFA-DA-07-001提交的”公告，宣布了有限的竞争 国家药物滥用治疗临床试验网络（U10）。“新英格兰节点（NNEN） 汇集研究专业知识，复杂的社区治疗计划（CTP）和各种各样的 在各种环境和多个护理中接受治疗的患者。该节点的特征是 学术研究人员与基于社区的治疗提供者之间的合作伙伴关系在5个新的 英格兰国家在基于社区的治疗中设计和实施成瘾治疗研究 程序。 自2002年进入CTN以来，NNEN已表现出取得的出色进度，结合了 科学和行政领导以及出色的试验表现。 NNEN是A上的铅节点 处方阿片类镇痛依赖性治疗的多站点研究，并发挥了一项重要的科学性研究 在两项使用药物使用的患者的CTN研究开发和实施中的领导作用 障碍和注意力缺陷多动障碍。参与体现了行政领导 NNEN成员在4个关键CTN国家委员会中； NNEN是唯一在 所有这些委员会。 NNEN成员还当选为几个国家委员会主席， 工作组，证明了他们在CTN同事中的良好声誉。试验性能具有 典范：NNEN参加了更多的试验，并且比其他任何人都随机分配了更多的参与者 节点于2002年进入；并且在2005-2006节点中随机分配了两倍以上的参与者 试验性能报告比CTN节点的平均值。而且，根据最新的NIDA 试验进度报告，NNEN是唯一的节点（除了2005年进入CTN的两个新节点以外） 满足或超过节点输入每个试验的每个性能指标的期望。 nnen CTP采用了许多新的基于证据的实践，并已经传播了 有关这些实践在地区，国内和国际上的信息。 该提议突出了北部新英格兰节点在资金期间的成就 自2002年9月以来。尽管节点取得了不佳的进度，但该提案还详细介绍了一个数字 在续签期间增强NNEN的增强。在接下来的三年中，NNEN 计划通过实施和测试最先进的药物滥用来继续推进CTN的任务 治疗干预措施，以便临床计划将使用可用的最佳治疗方法，患者将 获得成瘾治疗的不断发展的科学的全部利益。